- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02473133
Study of Interest of Personalized Radiotherapy Dose Redistribution in Patients With Stage III NSCLC (RTEP7)
Randomized Phase II-III Study of Personalized Radiotherapy Dose Redistribution in Patients With Inoperable Stage III Non-small Cell Lung Cancer and a Persistent FDG Uptake at 42 Grays During Concomitant Radio-chemotherapy
In patients with locally advanced stage III non-small cell lung cancer, the probability of local control remains low (about 17% at 1 year). Concomitant radio-chemotherapy is the standard treatment. An increase in total radiotherapy dose (from 66 to 74 Gray) has been proposed to improve local control, with contradictory results.
Relevant FDG-PET scan images can be acquired during radio-chemotherapy, with a demonstrated prognostic impact and recently in a multicentre prospective study. A significant reduction in FDG uptake / volume (metabolic response) suggests that the radiotherapy target volume could be reduced during radiotherapy possibly improving organs at risk tolerance. Conversely, a lack of metabolic response may justify treatment intensification before the end of radiotherapy. The investigators hypothesis is to investigate the individual tumour heterogeneity on FDG-PET during radio-chemotherapy to reduce the volume to a biological target that could receive a higher total dose (personalized dose redistribution).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigators objective is to determine whether tumour radiotherapy dose escalated up to 74 Gy in 6.6 weeks can improve the disease Local Regional Control rate at 15 months (1 year after completion of RCT) by adapting radiotherapy target volume to the metabolic response as assessed on FDG-PET/CT performed at 42 Gy of concomitant radio-chemotherapy in stage III non-small cells lung cancer and warrant more extensive phase III study.
Eligible patients will be allocated to one of 2 treatment groups:
- Arm A: Patients in the experimental arm will receive an individualized radiotherapy prescription up to a total dose of 74 Gy given in 6.6 weeks if they have a positive FDG-PET at 42Gy.
- Arm B: Patients in the standard arm will receive a single prescription of 66 Gy in 33 fractions in 6.6 weeks, with 2 Gy fractions given once daily, 5 days a week, without target volume reduction or adaptation (whatever the FDG-PET result).
In both arms, all patients will undergo 2 cycles of induction chemotherapy (based platinum salts) and a curative radio-chemotherapy. In both arms all fields must be treated daily.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Pierre Vera, MD, PhD
- Phone Number: 0232082258
- Email: pierre.vera@chb.unicancer.fr
Study Contact Backup
- Name: Doriane Richard, PhD
- Phone Number: 0232082985
- Email: doriane.richard@chb.unicancer.fr
Study Locations
-
-
-
Rouen, France, 76038
- Recruiting
- Centre Henri Becquerel
-
Contact:
- Pierre Vera, MD, PhD
- Phone Number: 0232082258
- Email: pierre.vera@chb.unicancer.fr
-
Contact:
- Doriane Richard, PhD
- Phone Number: 0232082985
- Email: doriane.richard@chb.unicancer.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female patients,
- Age over 18 years and below 75-year-old,
- Good general condition: WHO performance status ≤ 1,
- Histological evidence of non-small cell lung cancer,
- Measureable tumour according to RECIST 1.1 evaluation criteria,
- Mediastinoscopy or endobronchial ultrasound to prove the histological stage N2/N3,
- Patient eligible to curative-intent radio-chemotherapy,
- Absence of pleural involvement, of pulmonary or extra-thoracic metastatic localisation,
- Absence of co-morbidity contra-indicating radio-chemotherapy,
- Lung function: FEV1 ≥ 40% of theoretical value and DLCO/VA ≥ 60% of theoretical value and PaO2 ≥ 60 mm Hg,
- Tumour FDG uptake higher than mediastinal background noise on baseline PET/CT,
- Haematological parameters:
- Neutrophil count ≥ 1.5x109/L and platelet count ≥ 100x109/L,
- Haemoglobin ≥ 9 g/dL,
- Provisional RT plan confirming that the dose objectives (minimal dose of 62.7 Gy (95% of the prescribed dose) in 98% of target volumes and 70.3 Gy for the "boosted" volume at 74 Gy) and constraints (lungs, spinal cord) are met (ICRU83),
- Estimated creatinine clearance ≥ 60 mL/min,
- Signed informed consent
- Affiliated or beneficiary of a social benefit system
Exclusion Criteria:
- Histology other than non-small cell lung cancer,
- Absence of FDG uptake on FDG-PET/CT scan before induction chemotherapy,
- Patients for whom curative radiotherapy is not indicated (tumour extension, metastases, general condition, co-morbidities),
- Significant interstitial disease on CT scan,
- Previous neoplastic disease of less than 5 years duration or progressive (without basal cell carcinoma of the skin, in situ carcinoma of the cervix),
- Previous thoracic radiotherapy,
- Patient enrolled in another therapeutic trial,
- Pregnant women or women of child-bearing potential or breast feeding mothers,
- Adult subjects who are under protective custody or guardianship,
- Patient unable to comply with the specific obligations of the study (geographic, social or physical reasons),
- Uncontrolled diabetes with blood glucose ≥10 mmol/L,
- Hypersensitivity to the active substance (FDG) or to any of the excipients,
- Patients unable to understand the purpose of the study (language, etc.).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Personalized dose redistribution
Patients in the will receive an individualized radiotherapy prescription up to a total dose of 74 Gy given in 6.6 weeks if they have a positive FDG-PET at 42Gy (about two thirds of patients are expected as positive).
An initial dose of 50 Gy will be delivered in 5 weeks (single daily fractions of 2 Gy), then an additional dose up to 24 Gy will be delivered over 1.6 week using a twice-a-day fractionated radiotherapy.
|
Patients will receive an individualized radiotherapy prescription up to a total dose of 74 Gy given in 6.6 weeks if they have a positive FDG-PET at 42Gy.
An initial dose of 50 Gy will be delivered in 5 weeks (single daily fractions of 2 Gy), then an additional dose up to 24 Gy will be delivered over 1.6 week.
Other Names:
|
SHAM_COMPARATOR: No dose redistribution
Patients will receive a single prescription of 66 Gy in 33 fractions in 6.6 weeks, with 2 Gy fractions given once daily, 5 days a week, without target volume reduction or adaptation (whatever the FDG-PET result).
|
Patients will receive a single prescription of 66 Gy in 33 fractions in 6.6 weeks, with 2 Gy fractions given once daily, 5 days a week, without target volume reduction or adaptation (whatever the FDG-PET2 result).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Local regional control rate
Time Frame: one year
|
LCR rate (responders or stable disease) at 1 year after completion of RCT (M15 visit).
Disease progression will be assessed by RECIST 1.1 criteria
|
one year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of local regional control with RECIST 1.1 criteria
Time Frame: assessed at 9 months, 15 months, 27 months and 39 months
|
Disease progression will be assessed by RECIST 1.1 criteria
|
assessed at 9 months, 15 months, 27 months and 39 months
|
interval from the date of registration to date of local or regional progression
Time Frame: 3 years
|
the interval from the date of registration to date of local or regional progression
|
3 years
|
Percentage of severe (grade 3+ CTCAE, v4) radiation-induced toxicity affecting lung and oesophagus at M9 visit (early toxicity) and M15, M27, M39 visits (late toxicity),
Time Frame: assessed at 9 months, 15 months, 27 months and 39 months
|
Percentage of severe (grade 3+ CTCAE, v4) radiation-induced toxicity affecting lung and oesophagus at M9 visit (early toxicity) and M15, M27, M39 visits (late toxicity),
|
assessed at 9 months, 15 months, 27 months and 39 months
|
Percentage of patients in arm A for whom the radiotherapy dose could be increased
Time Frame: 6.6 weeks
|
Percentage of patients in arm A for whom the RT dose could be increased
|
6.6 weeks
|
correlation of progression free survival with PET measure
Time Frame: one year
|
standardized uptake value max and metabolic tumor volume of FDG -PET2 will be correlated with progression free survival at M15 visit
|
one year
|
correlation of overall survival with PET measure
Time Frame: one year
|
standardized uptake value max and metabolic tumor volume of FDG -PET2 will be correlated with overall survival at M15 visit
|
one year
|
Change in standardized uptake value max
Time Frame: weeks 12
|
Measurements of the relative change in SUVmax from the 18F-FDG -PET1 (baseline) to the FDG -PET2 at 42 Gy defined as [(PET2- PET1) / PET1] x 100%
|
weeks 12
|
Change in metabolic volume
Time Frame: weeks 12
|
Measurements of the relative change metabolic tumour volume from the 18F-FDG -PET1 (baseline) to the FDG -PET2 at 42 Gy defined as [(PET2- PET1) / PET1] x 100%
|
weeks 12
|
Overall Survival
Time Frame: assessed at 9 months, 15 months, 27 months and 39 months
|
overall survival after M9, M15, M27, M39 follow-up visits
|
assessed at 9 months, 15 months, 27 months and 39 months
|
progression-free survival
Time Frame: assessed at 9 months, 15 months, 27 months and 39 months
|
progression-free survival after M9, M15, M27, M39 follow-up visits
|
assessed at 9 months, 15 months, 27 months and 39 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Peirre Vera, MD,PHD, Centre Henri Becquerel
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHB14.04/IFCT14-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-small Cell Lung Cancer
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
-
Karen KellyBristol-Myers Squibb; National Cancer Institute (NCI); TransgeneCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung CancerUnited States
-
Memorial Sloan Kettering Cancer CenterAstraZenecaRecruitingNSCLC | Lung Cancer | Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | PD-L1 Gene Mutation | Non-small Cell Lung Cancer Stage IIIA | Non-small Cell Lung Cancer Stage IIUnited States
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)WithdrawnStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
Clinical Trials on Personalized dose redistribution
-
University of Alabama at BirminghamRecruitingParkinson DiseaseUnited States
-
ArjohuntleighMagellan Medical Technology Consultants, Inc.UnknownPressure UlcerUnited States, Canada
-
Hospital de Clinicas de Porto AlegreConselho Nacional de Desenvolvimento Científico e TecnológicoNot yet recruiting
-
Northwell HealthNational Institute on Aging (NIA)RecruitingSleep InsufficiencyUnited States
-
Hangzhou Normal UniversityCompletedPatients in Minimally Conscious State
-
University of LouisvilleNational Institute of General Medical Sciences (NIGMS)Not yet recruiting
-
Taipei Medical UniversityCompletedCritical Illness | Mechanical VentilationTaiwan
-
Hospital de Clinicas de Porto AlegreUnknownDepressive Symptoms | COVID | Irritability | Mental Health Wellness 1 | Anxiety Symptoms | Emotional Distress | TelepsychotherapyBrazil
-
University of CopenhagenUniversity of Parma; Fundació Eurecat; ONMI; Simple Feast; AlimentómicaCompletedObesity | Overweight | Metabolic SyndromeDenmark
-
Washington University School of MedicineNational Institute of Mental Health (NIMH)Completed